Sign up online today & collaborate
or click here to find out more
Abingdon, UK – AMSBIO has introduced new cell lines and controls for Programmed Cell Death Protein 1 (PD-1) research, and to test inhibitors of the PD-1 / PD-L1 pathway.
The binding of PD-1, a receptor expressed on activated T-cells, to its ligands (PD-L1 and PD-L2) negatively regulates immune responses. PD-1 ligands are highly expressed in many cancers, and their interaction inhibits T-cell activity allowing cancer cells to escape immune surveillance. The PD-1: PD-Ligands pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.
A PD-1 / NFAT Reporter – Jurkat Cell Line is now available for applications including screening for activators or inhibitors of PD-1 signaling in a cellular context and also for characterizing the biological activity of PD-1 and its interactions with ligands.
AMSBIO has also introduced the accompanying TCR activator / PD-L1 – CHO Recombinant Cell line that is purpose designed for screening for activators or inhibitors of PD-1 signaling as well as screening PD-L1 antibodies for their binding affinity.
The functionality of the cell lines was validated using a PD-1:PD-L1 cell-based assay and expression of human PD-1 or PD-L1 in the cell lines was confirmed by Western blotting.
AMSBIO offers a wide range of purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, the company offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.